Carbamazepine offers no psychotropic advantage over phenytoin in adult epileptic subjects.
We compared 19 men on carbamazepine (CBZ) monotherapy with 19 men on phenytoin (PHT) monotherapy, all of whom had standard therapeutic levels. The two groups were matched for age, sex, education, premorbid predicted IQ, seizure frequency, duration, number, type and aetiology, weekly ethanol consumption and psychiatric history. The two groups did not differ statistically on self- and reliable-informant rated personality inventories, word recognition, face recognition, confrontation naming, finger oscillation or trailmaking series completion times. These data fail to support a behavioural and cognitive advantage of CBZ over PHT in adult epileptics.
Verma
N P
NP
Epilepsy Center of Michigan, Southfield 48076.
Yusko
M J
MJ
Greiffenstein
M F
MF
D000328:Adult; D002220:Carbamazepine / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography / Q000187:drug effects; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007360:Intelligence / Q000187:drug effects; D008297:Male; D011939:Mental Recall / Q000187:drug effects; D008875:Middle Aged; D009483:Neuropsychological Tests; D010555:Personality Inventory; D010672:Phenytoin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
D002220:Carbamazepine; D010672:Phenytoin